反应详情

The title compound was prepared by substituting N-(tert-butoxycarbonyl)-N-methyl-L-leucine for (S)-2-(tert-butoxycarbonyl(methyl)amino)-4,4-dimethylpentanoic acid and (3aR,4S,6aS)-2-(5-(trifluoromethyl)pyridin-2-yl)octahydrocyclopenta[c]pyrrol-4-amine from Example 262 Step B for (3aR,4S,6aS)-2-(6-(trifluoromethyl)pyridin-2-yl)octahydrocyclopenta[c]pyrrol-4-amine in the procedure described in Example 587: 1H NMR (400 MHz, pyridine-d5) δ ppm 8.63 (s, 1H), 8.37 (d, J=7.5, 1H), 7.68 (dd, J=8.9, 2.5, 1H), 6.40 (d, J=8.9, 1H), 4.49-4.38 (m, 1H), 3.83 (d, J=10.7, 1H), 3.68 (dd, J=11.0, 7.3, 1H), 3.63-3.52 (m, 1H), 3.33 (d, J=8.2, 1H), 3.27 (dd, J=8.3, 5.9, 1H), 2.77 (h, J=8.8, 2H), 2.45 (s, 3H), 2.17 (dt, J=12.4, 7.1, 1H), 2.14-1.98 (m, 1H), 2.02-1.86 (m, 2H), 1.79-1.67 (m, 2H), 1.66-1.55 (m, 1H), 1.48-1.36 (m, 1H), 0.94 (d, J=6.6, 3H), 0.88 (d, J=6.6, 3H); MS (ESI+) m/z 399 (M+H)+.